News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT Parkinson’s trial resumes patient recruitment

LCT Parkinson’s trial resumes patient recruitment

23 June 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.

“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments.

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor.

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s.

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of indications.

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Free Diving: William Trubridge Breaks World Record

With just a single breath, New Zealand free diver William Trubridge has successfully broken his own unassisted free dive world record of 101 metres. More>>

ALSO:

RLWC 2017 Draw: New Zealand Set For A Festival Of Rugby League

New Zealand Rugby League fans will have the chance to see the Kiwis in action against the best in the Pacific region for the Rugby League World Cup 2017, as announced today at the Official Tournament Draw. More>>

ALSO:

Non-Pokemon News: Magical Park A Safer Augmented Reality For Younger Audiences

Since May, Wellington City Council has been trialling a new app, Magical Park, in collaboration with the game’s New Zealand developer Geo AR Games, in parks around the city. Magical Park uses GPS technology to get users moving around the park to play within a set boundary. More>>

'Erroneous': Pokemon App Makers On Huge Privacy Flaw

We recently discovered that the Pokémon Go account creation process on iOS erroneously requests full access permission for the user's Google account... More>>

ALSO:

Te Wiki O Te Reo: Te Reo Māori Is For All New Zealanders — Minister

Minister for Māori Development Te Ururoa Flavell welcomes the start of Māori Language Week today and invites all New Zealanders to give speaking te reo Māori a go. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news